Nuciferine, an alkaloid found in Nelumbo nucifera leaves, alleviates dyslipidemia in vivo. However, whether it improves liver injury in diabetic conditions and the underlying mechanism is unclear. The present study aimed to investigate the effects of nuciferine on lipid and glucose metabolism in a murine model of Type 2 diabetes mellitus (T2DM) and to determine the underlying mechanisms of these effects.
Introduction
Type 2 diabetes mellitus (T2DM) is a debilitating chronic disease that has become one of the most rapidly escalating epidemics worldwide. Globally, an estimated 422 million adults were living with diabetes in 2014 (WHO, 2016) . The prevalence of diabetes has increased in China in recent years, and nearly 12% of Chinese adults are currently suffering from this condition (Xu et al., 2013) . T2DM patients have a higher risk (35-80%) of developing hepatic steatosis compared to non-diabetic individuals (Loomba and Sanyal, 2013) . The liver is a key organ in maintaining lipid and energy homeostasis, and the excess lipids are stored in the liver as fat droplets, which can eventually lead to inflammation, insulin resistance and diabetes. Another major metabolic consequence of diabetes is the abnormal deposition of triglycerides (TG) in hepatocytes, which further promotes hepatic steatosis (Bril and Cusi, 2017) . Hepatic lipid accumulation is closely related to de novo lipogenesis, lipid transport and lipid consumption (McGarry and Foster, 1980; Cahill Jr, 2006) . One of the central processes in hepatic lipid metabolism is the oxidation of fatty acids, which is regulated, at least in part, by some key transcription factors such as PPARα (Mandard et al., 2004) and its coactivator PPARγ coactivator-1α (PGC1α) (Vega et al., 2000) .
The PPARs regulate the expression of crucial genes related to metabolic diseases including obesity, dyslipidemia and diabetes (Grygiel-Gorniak, 2014) . PPARα is predominantly expressed in the liver (Yang et al., 2017) and plays an important role in maintaining lipid homeostasis. It promotes fatty acid β-oxidation by modulating the respective genes (Escher et al., 2001) , and PPARα activators also improve glucose metabolism in T2DM by increasing insulin sensitivity and reducing hyperglycaemia and hyperinsulinaemia (Guerre-Millo et al., 2000) . The transcriptional coactivator PGC1α also modulates the expression of key metabolic enzymes involved in gluconeogenesis, fatty acid oxidation and oxidative phosphorylation in the liver through its functional interaction with the PPARs (Lin et al., 2005) . As PGC1α is also involved in T2DM (Finck and Kelly, 2006; Wu et al., 2016) , activation of the PPARα/PGC1α axis may serve as a potential therapeutic intervention by improving lipid metabolic dysfunction in diabetic patients.
There has been a growing interest in natural products for treating T2DM (Tahrani et al., 2016) . Nuciferine (PubChem CID: 10146, Figure 1A ), an aromatic ringcontaining alkaloid, isolated from the leaves of Nelumbo nucifera, has been used in traditional Chinese medicine for treating obesity, heliosis and bleeding (Ono et al., 2006; Wang et al., 2015; Sharma et al., 2017) . It has also been shown to alleviate dyslipidemia and hepatic steatosis in high-fat diet (HFD)-fed hamsters (Guo et al., 2013) . However, whether nuciferine ameliorates liver injury in diabetic conditions and the molecular mechanism(s) of such potential actions is unclear. The aim of the present study was to determine the effects of nuciferine on lipid and glucose metabolism in an HFD/streptozocin (STZ)-induced T2DM mouse model and to elucidate the underlying mechanisms.
Methods

HFD/STZ-induced T2DM in mice and nuciferine administration
All animal care and experimental procedures were approved by the Ethics of Animal Experiments Committee of Xi'an Jiaotong University (Xi'an, Shaanxi, China, approval no. XJTULAC2016-272) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) . Six-week-old male C57BL/6J mice were housed in 24°C with a 12 h light/dark cycle. After 1 week of acclimatization to the environment, the mice were randomly divided into four groups: a normal control group (NC; n = 10), a diabetic model control group (DC; n = 10), a low-dose nuciferine treatment group (Nuci-L; n = 10) and a high-dose nuciferine treatment group (Nuci-H; n = 10). The mice in the normal group were given a standard diet (Research Diet, D12450B, 10% calories from fat), and the mice in the other groups were fed with HFD (Research Diet, D12492, 60% calories from fat) during the experimental period. The mice in the Nuci-L and Nuci-H groups were fed with HFD, supplemented with 0.06% (w/w) or 0.12% (w/w) nuciferine respectively. After feeding the HFD for 6 weeks in DC and nuciferine treated groups, the mice were fasted for 12 h overnight and then injected i.p. with STZ (35 mg·kg À1 , dissolved at 0.1 mM cold citrate buffer, pH 4.4) for 3 days to induce T2DM (Nath et al., 2017) . Meanwhile, the NC group was injected with citrate buffer. Body weights were measured weekly during the experimental period.
Intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance tests (IPITT)
The IPGTT and IPITT were performed as previously described (Wang et al., 2012) . Briefly, in the last week of treatment, after fasting overnight (12 h), a blood sample was immediately taken from each mouse and then a glucose solution (2.5 g·kg À1 ) was injected i.p. without delay. Blood samples were withdrawn from tails of each mouse at 30, 60, 90 and 120 min intervals after the injection (Durschlag et al., 1996) . The IPITT was performed on another day. The mice were fasted for a period of 4 h and then injected i.p. with insulin (0.8 U·kg À1 ) after measuring the baseline glucose levels.
Glucose levels in tail blood were determined at 15, 30, 45 and 60 min after the insulin injection. The AUC was calculated from these measurements.
Analysis of blood insulin levels
Mice were fasted overnight. After the mice were fully anaesthetized, the blood samples were collected from the ophthalmic vein and centrifuged at 1000× g for 10 min at 4°C. The plasma was collected and stored at À80°C until use. Serum insulin was determined using ELISA according to the instructions from the manufacturer (SBJ-M0417, Nanjing SenBeiJia Biological Technology Co., Ltd., Nanjing, China). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the formula HOMA-IR = [fasting plasma glucose (mmol·L
À1
) × fasting plasma insulin (mU·L
)]/22.5.
Liver injury markers and lipid profile analysis
After killing the mice, serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assayed using commercially available kits (Nanjing, Jiancheng, China) according to the manufacturer's introductions. The liver tissues were collected and weighed. The same part of the liver tissue was homogenized in the tissue lysis buffer containing 1% Triton X-100. Liver total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and TG levels were quantified using appropriate kits (Nanjing, Jiancheng, China).
Immunohistochemical analysis of liver
Liver tissues were fixed in 4% neutral-buffered formalin for 24 h. Then, the tissues were embedded in paraffin after dehydration in a graded ethanol series (70-100%). Embedded samples were sectioned (6 μm thick) with a rotary microtome and mounted on slides. For immunohistochemical analysis, after microwave-based heating antigen retrieval, sections were then incubated with mouse PGC1α antibody (1:100) at 4°C overnight, followed by biotin-streptavidin HRP detection systems using SPlink Detection Kits (SP-9000, ZSGB-BIO, Peking, China 
Cell culture assays
Human HepG2 cells (ATCC, USA) were cultured in DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS (Gibco) and 1% penicillin streptomycin solution (30-002-CI, Corning, New York, NY, USA) at 37°C under a humidified atmosphere of 5% CO 2 and 95% air. Palmitic acid was dissolved in ethanol (150 mM), heated at 65°C for 15 min and vortexed to dissolve completely. This solution (150 mM) of palmitic acid was filter sterilized and diluted 1:20 with double-distilled H 2 O containing 10% BSA to yield a final stock solution concentration of 7.5 mM. This mixture was incubated at 37°C for 60 min to allow the palmitic acid to conjugate with BSA. HepG2 cells (10 6 cells mL -1 per well) in DMEM, supplemented as above, were incubated in a 6 well culture dish and pretreated with nuciferine (10 μM) for 12 h, followed by incubation with the palmitic acid/BSA conjugated solution (final concentration 150 μM) for 24 h. The NC group of HepG2 cells were treated with the equivalent BSA solution (final concentration 0.2 % BSA) without palmitic acid.
PPARα transactivation assay
PPARα transactivation was determined using a luciferase reporter pGL3 vector containing three peroxisome proliferator response elements (PPRE X3-TK-LUC) as previously described (Huang et al., 2014) . When the cells reached the density of 60%, pcDNA3.1 vector containing PPARα expression plasmid (0.9 μg), reporter plasmid PPRE X3-TK-LUC (0.3 μg) and pRSV-gal (0.1 μg, a plasmid expressing β-galactosidase) were transfected into HepG2 cells using Lipofectamine 2000. After transfection for 6 h, the HepG2 cells (10 6 cells mL -1 )
were incubated with palmitic acid (150 μM), with or without nuciferine (10 μM) for 36 h. Then, the cells were washed with PBS and harvested. The intensity of the emitted luminescence was determined using a multilabel reader (PerkinElmer, Waltham, MA, USA).
Small interfering RNA (siRNA) transfection siRNA was chemically synthesized by GenePharma Co., Ltd (Shanghai, China). After the cell density reached 60%, cells were transfected with siRNA duplex or control siRNA (50 nM) using Lipofectamine 2000 and incubated for 24 h. After transfection, the medium was changed to DMEM containing with or without 10 μM nuciferine for 12 h and then treated with palmitic acid for 24 h. The siRNA sequences are listed in Table 1 . Table 1 Primers used for RT-qPCR analysis and siRNA 
Reverse transcription-quantitative PCR (RT-qPCR)
Total RNA was extracted using TRIzol reagent according to the manufacturer's instructions. Total RNA was reversetranscribed into cDNA using the iScript cDNA synthesis kit (Promega, WI, USA), followed by qPCR with SYBR Green (Promega, WI, USA) using 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA). The reaction condition is as follows: stage 1, 95°C for 10 min and stage 2, 40 cycles of 95°C for 30 s, 60°C for 30 s and 72°C for 30 s. Gapdh was used as an internal control. The primer sequences are listed in Table 1 .
Immunoblotting
Immunoblotting was performed as described earlier (Yang et al., 2014) . Briefly, equal amounts of protein samples (40 μg) were separated by 10% SDS-PAGE, transferred to PVDF membranes and immunoblotted respectively with antibodies against PGC1α antibody (1:1000) or PPARα antibody (1:1000) at 4°C overnight. β-Actin (1:1000) was used as loading control. The membranes were then washed three times with Tris-buffered saline with Tween 20 (TBST) and incubated with the secondary antibody conjugated to antimouse (1:3000) or anti-rabbit (1:3000) HRP-conjugated secondary antibodies for 1 h. Bands weredetected by enhanced chemiluminescence using enhanced chemiluminescence (ECL) and visualized by exposure to X-ray films.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Quantitative data are presented as mean ± SEM. Data analyses were performed using SPSS 18.0 (SPSS, Inc., Chicago, IL, USA). Statistically significant differences between two groups were assessed using Student's t-test and for more than two groups, with one-way ANOVA followed by Dunnett's post-test. P < 0.05 was considered statistically significant.
Materials
Nuciferine was purchased from Chengdu Biopurify Phytochemicals Ltd. (Chengdu, China 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) . NHR=PPAR ? enzymes?
Results
Nuciferine improves glucose metabolism and insulin sensitivity in diabetic mice HFD/STZ-induced diabetic mice were fed 0.06% or 0.12% (w/w) nuciferine mixed with their chow for 14 weeks, and their glucose tolerance was evaluated by IPGTT ( Figure 1B) . The blood glucose in all the mice reached peak levels 15 min after i.p. glucose loading and then decreased to normal levels within 120 min. The DC group had the highest blood glucose level at every time point compared with the NC group. In contrast, nuciferine-treated mice had significantly lower glucose levels compared to the untreated diabetic mice, and similar levels to that of the NC group, regardless of the dose. AUC results also showed similar effects indicating that nuciferine improved glucose metabolism in diabetic mice ( Figure 1C ). Insulin resistance was measured by IPITT, which showed that the glucose levels in the NC group significantly decreased 15 min after insulin injection and recovered to the normal level within 60 min ( Figure 1D ). While the DC group showed a slight decrease in glucose levels compared to the NC group, plasma glucose levels were markedly reduced upon nuciferine treatment compared with the untreated diabetic mice. The AUC results again showed similar effects indicating that nuciferine restored peripheral insulin sensitivity in diabetic mice ( Figure 1E ). HOMA-IR measurements showed that HFD combined with STZ injection significantly increased insulin resistance in the DC group compared with the NC group (P < 0.05; Figure 1F ). However, both the Nuci-L and Nuci-H groups showed significant improvements in insulin sensitivity compared to the DC group (P < 0.05), and no significant differences were seen between the two nuciferine doses. Taken together, nuciferine not only restored the impaired glucose tolerance but also improved insulin resistance in HFD/STZ-induced diabetic mice.
Nuciferine attenuated liver injury and lipid accumulation in diabetic mice
The changes in the body weights of the mice during the entire feeding period are shown in Figure 2A . There was no significant intragroup variation in the basal body weights, but after 4 weeks of HFD/STZ induction, the DC group had gained significantly more weight than the NC group up to the final day of the experiment. Nuciferine treatment significantly attenuated the increase in body weight from the 6th week onwards.
At the final week of treatment, body weight gains of Nuci-L and Nuci-H groups were 39 and 32%, respectively, which were markedly lower than that of the DC group (57%). Biochemical markers of liver injury (AST and ALT) were also analysed ( Figure 2B ,C). Compared with the NC group, the DC group had significantly higher serum levels of ALT and AST, which were improved by nuciferine treatment. While serum ALT levels were decreased in both Nuci-L and Nuci-H groups, serum AST was only decreased in the Nuci-H group. These results indicated that nuciferine ameliorated liver injury in HFD/STZ-induced T2DM mice in a dose-dependent manner. Furthermore, hepatic lipid profiling showed that the TC, LDL-C and TG levels in the livers of the DC group mice significantly increased by 157, 140 and 73%, respectively, compared to the NC group mice ( Figure 2D,E) . In contrast, LDL-C and TG levels in the Nuci-L and Nuci-H groups were respectively~40 and~55% lower compared to the DC group (P < 0.05). In contrast, there were no differences in the HDL-C levels among the groups. Oil red O staining was performed on liver cryosections to detect hepatic steatosis ( Figure 2F ). No histopathological changes were observed in the NC group, while increased deposition of small lipid droplets were seen at the lobular margins in the liver of the DC group mice. Nuciferine treatment did not completely prevent hepatic steatosis but decreased the size of the lipid droplets regardless of dose. Taken together, nuciferine significantly attenuated lipid accumulation in the livers of HFD/STZ-induced diabetic mice.
Nuciferine regulated PPARα expression and transactivation in diabetic mice and HepG2 cells treated with palmitic acid
To understand the molecular mechanism of nuciferine action on lipid accumulation in diabetic mice, the expression of genes involved in lipid metabolism were analysed. Nuciferine significantly increased the expression of both PPARα protein ( Figure 3A ) and mRNA in the livers of diabetic mice, indicating that nuciferine might also affect the transcriptional activities of PPARα ( Figure 3B ). Therefore, genes involved in lipid β-oxidation, such as Acox1, Ehhadh and Fgf21, were also analysed by RT-qPCR ( Figure 3B ). All these genes were significantly up-regulated in the Nuci-L and Nuci-H groups, indicating that nuciferine treatment activated PPARα transcriptional activity in the liver of diabetic mice. To further verify the anti-steatotic effect of nuciferine in vitro, HepG2 cells were treated with the alkaloid, following exposure to palmitic acid (C16:0). PPARα inhibition induced by palmitic acid was attenuated by nuciferine, which restored PPARα mRNA and protein to the normal levels ( Figure 3C,D) . In addition, PA-induced down-regulation of Acox1, Ehhadh and Fgf21 was also restored in the nuciferine treated group ( Figure 3D ), which corresponded to the in vivo results. To determine whether nuciferine directly activated PPARα transcriptional activity, HepG2 cells were transfected with the PPRE-driven luciferase reporter and PPARα expression plasmid and cultured in the presence or absence of nuciferine along with palmitic acid. Nuciferine directly reversed palmitic acid-induced inhibition of PPARα transcriptional activity ( Figure 3E ). To further confirm the relationship between these genes and PPARα, HepG2 cells were transfected with si-PPARα ( Figure 3F ). Knocking down PPARα significantly down-regulated Acox1 and Fgf21 compared with the control ( Figure 3G ), thus confirming that PPARα controls the expression of these genes involved in fatty acid oxidation. Taken together, nuciferine not only up-regulated the expression of PPARα but also directly activated its transcriptional activity in the liver.
The effects of nuciferine are mediated by PGC1α
As a transcriptional coactivator of PPARα, PGC1α regulates the expression of the key enzymes of fatty acid oxidation through its functional interaction with the PPARs. To further investigate the mechanism of the protective effect of nuciferine, PGC1α expression levels were first analysed in vivo, and a significant decrease in both PGC1α mRNA and protein was seen in the diabetic mice ( Figure 4A-C) . In addition, treatment with palmitic acid significantly decreased PGC1α expression in the HepG2 cells compared to the controls ( Figure 4D ,E). However, nuciferine restored the expression of PGC1α in both the livers of diabetic mice and in HepG2 cells.
To determine whether activation of PPARα by nuciferine depends on PGC1α up-regulation, HepG2 cells were transfected with si-PGC1α, which specifically inhibited the expression of PGC1α protein ( Figure 5A ). Nuciferinemediated activation of Acox1, Ehhadh and Fgf21 was effectively abolished by PGC1α silencing, indicating that nuciferine up-regulated PPARα via PGC1α (Figure 5B-D) . To test whether PGC1α directly activated PPARα transcriptional activity, HepG2 cells were transfected with the PPRE-driven luciferase reporter and PPARα expression plasmid with or without si-PGC1α ( Figure 5E ). A significant decrease in luciferase activity was seen in cells with PGC1α silencing compared to the control cells, indicating that PGC1α played a direct role in PPARα transcriptional activity.
Discussion
Recent studies have shown beneficial effects of nuciferine in various metabolic diseases. It can alleviate lipogenesis and inflammation in HepG2 cells and 3T3-L1 adipocytes . In addition, nuciferine stimulated glucose consumption in 3T3-L1 adipocytes (Ma et al., 2014) or insulin secretion by pancreas islet beta cells (Nguyen et al., 2012) . However, the pharmacological utility of nuciferine is not completely clear due to lack of in vivo results. One study has reported that nuciferine potently ameliorated HFDinduced hepatic steatosis and injury in hamsters (Guo et al., 2013) , but the underlying mechanism was not studied. It was also not clear whether nuciferine ameliorated liver injury in diabetic conditions. We tested the effect of nuciferine on a well-established diabetic mice model, which is induced by HFD feeding along with i.p. STZ injection (Srinivasan et al., 2005; Skovsø, 2014; Nath et al., 2017) . HFD causes insulin resistance and glucose intolerance and the STZ treatment severely reduces beta-cell function. Diabetic indicators, including IPGTT, IPITT and HOMA-IR, indicated that nuciferine not only regulated glucose metabolism but also improved insulin sensitivity. Hepatic steatosis is a frequent complication of diabetes and frequently coexists with T2DM. Imbalances in hepatic lipid metabolism lead to the accumulation of hepatic TG and insulin resistance, finally causing diabetes (Perry et al., 2014) . The plasma lipid profile of nuciferine-treated diabetic mice in our study showed similar trends to that seen with the HFD-fed hamster model treated with nuciferine (Guo et al., 2013) . In addition, p.o. administration of nuciferine also significantly reduced lipid accumulation in the liver of diabetic mice. We used different doses of nuciferine (0.06% w/w or 0.12% w/w) in our study but did not see any dose-dependent effects, most likely because the doses we used were higher. Together, our findings demonstrated that nuciferine had protective effects on hepatic lipid metabolism in HFD/STZ-induced diabetic mice.
Abnormal hepatic accumulation of TG is often associated with T2DM. Improvement of lipid metabolism halts the efflux of fatty acids from adipose tissue to the liver and thus alleviates liver injury in diabetes (Sun and Lazar, 2013) . Several studies have shown simultaneous up-regulation of gluconeogenesis and lipogenesis in diabetics, leading to excessive lipid production, more than the liver can handle (Adiels et al., 2008) . Hepatic fatty acid oxidation plays an important role in fatty acid catabolism along with diabetic pathogenesis (Wakil and Abu-Elheiga, 2009; Murea et al., 2010) . PPARα is a critical transcriptional regulator of several key enzymes involved in lipid metabolism. We found that nuciferine up-regulated the expression of PPARα and its target genes involved in fatty acid oxidation in the liver of diabetic mice, as well as in HepG2 cells in vitro. Nuciferine also reinforced the binding of activated PPARα to PPRE as shown by the reporter assay, confirming that nuciferine directly increased PPARα transcriptional activity ( Figure S1 ). Activation of PPARα has been shown to lower both TG and LDL metabolism (Fruchart, 2009 ). In addition, PPARα knockout suppressed the expression of genes involved in fatty acid oxidation in murine fatty liver (Aoyama et al., 1998) . Therefore, one alternative therapeutic strategy for diabetes could be the amelioration of hepatic steatosis by activating PPARα. Another finding of this study is that the expression of PGC1α in the liver of T2DM mice increased during nuciferine treatment. PGC1α facilitates the transcription of genes related to mitochondrial and lipid oxidation (Ventura-Clapier et al., 2008) . One study showed that PGC1α was a hepatocyte-derived hormone that restored lipid homeostasis in obesity-induced diabetes (Liu and Lin, 2011) . Furthermore, systemic or liver-specific knockout or knockdown of PGC1α in mice caused hepatic steatosis, triglyceride accumulation and fasting hypoglycemia (Estall et al., 2009) . PGC1α is also a coactivator of PPARα and controls the expression of genes encoding the fatty acid oxidation enzymes by interacting with PPARα (Vega et al., 2000) . PGC1α knockdown diminished the effects of nuciferine on hepatic lipid metabolism, thus confirming the coactivator role of PGC1α. Our results indicated that hepatic PGC1α plays an important role in regulating hepatic lipid metabolism, via the activation of the PPARα/PGC1α signalling pathway in liver. In addition, our findings suggest that increasing PGC1α expression might activate PPARα in the liver due to greater interaction between PGC1α and PPARα . However, this mechanism needs to be further investigated.
Other studies have also reported a relationship between levels of PGC1α and the risk of diabetes (Wu et al., 2016) . Estall et al. (2009) reported that chronic and mild down-regulation of hepatic PGC1α caused hepatic insulin resistance, affected triglyceride assembly and reduced gluconeogenesis. We measured the changes in PGC1α protein and mRNA levels after nuciferine treatment and found that nuciferine directly up-regulated PGC1α, which is consistent with the earlier findings. Another study suggested that selectively increasing PGC1α acetylation reduced gluconeogenic activity and reduced glucose release from isolated hepatocytes leading to suppressed hepatic glucose production (Sharabi et al., 2017) , indicating that PGC1α activity may be partly determined by post-translational modifications (Lira et al., 2010) . The effect of nuciferine on post-translational modifications of PGC1α should be further studied.
To summarize, the present study demonstrated that nuciferine improved lipid profiles and attenuated hepatic Nuciferine ameliorates hepatic steatosis steatosis in HFD/STZ-induced diabetic mice. Activation of PPARα/PGC1α might be one of the important pathways regulating hepatic lipid metabolism. Nuciferine is therefore a potential therapeutic candidate for improving hepatic steatosis and the management of T2DM. In conclusion, our results show for the first time that nuciferine attenuates dysregulated liver lipid metabolism in HFD/STZ-induced diabetic mice, at least partly via the PPARα/PGC1α signalling pathway ( Figure 6 ). 
Figure 6
Diagram of the possible molecular mechanisms involved in the attenuation of hepatic dyslipidemia in HFD/STZ-induced diabetic mice. Nuciferine increased the expression of PGC1α and PPARα and activated their downstream target genes related to fatty acid oxidation.
